Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 6 | 2 |
| List of Figures | 8 | 3 |
| Opioids Market to 2017: Introduction | 11 | 2 |
| GBI Research Report Guidance | 11 | 2 |
| Opioids Market: Market Overview | 13 | 29 |
| Introduction | 13 | 1 |
| Opioids: A Classification | 13 | 2 |
| Branded Generics Play a Major Role | 15 | 1 |
| Novel Drug Delivery Techniques Push Opioid Usage | 15 | 1 |
| Adverse Effects Associated With Opioids Restrain Its Prescription | 16 | 1 |
| REMS | 17 | 1 |
| What are REMS? | 17 | 1 |
| Implications of REMS | 18 | 1 |
| REMS for Opioids | 19 | 1 |
| Revenue | 20 | 1 |
| Major Marketed Opioids | 21 | 1 |
| Oxycontin | 21 | 1 |
| Overview | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| Efficacy Details | 21 | 1 |
| Safety Issues | 22 | 1 |
| Embeda | 22 | 1 |
| Overview | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| Efficacy | 22 | 1 |
| Safety Issues | 22 | 1 |
| Exalgo | 23 | 1 |
| Overview | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| Efficacy | 23 | 1 |
| Safety Issues | 23 | 1 |
| Onsolis | 24 | 1 |
| Overview | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| Efficacy | 24 | 1 |
| Safety Issues | 25 | 1 |
| Avinza | 25 | 1 |
| Overview | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| Efficacy Details | 25 | 1 |
| Safety Issues | 25 | 1 |
| Life Cycle Management | 26 | 1 |
| Duragesic | 26 | 1 |
| Overview | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| Safety Issues | 26 | 1 |
| Kadian | 27 | 1 |
| Overview | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| Safety Issues | 27 | 1 |
| Opana ER | 27 | 1 |
| Overview | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| Efficacy | 28 | 1 |
| Safety Issues | 28 | 1 |
| Vicodin CR | 28 | 1 |
| Overview | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| Safety Issues | 29 | 1 |
| Dolophine | 29 | 1 |
| Overview | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| Safety Issues | 29 | 1 |
| MS Contin | 30 | 1 |
| Overview | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| Safety Issues | 30 | 1 |
| Oramorph | 30 | 1 |
| Overview | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| Safety Issues | 31 | 2 |
| FDA Regulations Regarding Opioids | 33 | 1 |
| FDA Regulations on Opioid Combinations with Acetaminophen | 33 | 1 |
| Darvocet, Darvon (Propoxyphene) Withdrawn From the Market | 33 | 1 |
| Annual Cost of Therapy | 33 | 1 |
| Treatment Usage Patterns | 34 | 2 |
| Diseased Population | 36 | 1 |
| Treatment Seeking Population | 37 | 1 |
| Diagnosed Population | 38 | 1 |
| Prescription Population | 39 | 1 |
| Drivers and Restraints of the Opioids Market | 40 | 1 |
| Drivers | 40 | 1 |
| Rising Elderly Populations | 40 | 1 |
| Implementation of REMS will Reduce Safety Issues | 40 | 1 |
| Rise in Incidence of Indications Such as Cancer and Arthritis | 40 | 1 |
| Restraints | 41 | 1 |
| Opioid Usage is Associated with Several Adverse Affects | 41 | 1 |
| Addiction and Tolerance | 41 | 1 |
| Diversion | 41 | 1 |
| Weak pipeline | 41 | 1 |
| Opioids Market: Therapeutic Landscape | 42 | 79 |
| Opioids Market for Fibromyalgia | 42 | 1 |
| Introduction | 42 | 1 |
| Revenue and Forecasts | 42 | 2 |
| Annual Cost of Therapy | 44 | 1 |
| Treatment Usage Patterns | 45 | 1 |
| Diseased Population | 46 | 1 |
| Treatment Seeking Population | 47 | 1 |
| Diagnosed Population | 48 | 1 |
| Prescription Population | 49 | 1 |
| Geographical Segmentation | 50 | 2 |
| Drivers and Restraints for the Opioids Market for Fibromyalgia | 52 | 1 |
| Drivers | 52 | 1 |
| Elderly Populations Will Drive Prevalence | 52 | 1 |
| Improvements in Awareness and Resultant Diagnosis Levels Will Drive the Market | 52 | 1 |
| Substantial Unmet Need Increases the Market Potential | 52 | 1 |
| Restraints | 53 | 1 |
| Limitations in the Efficacy of Existing Drugs Leads Can Potentially Lead to Low Prescription | 53 | 1 |
| Inadequate Knowledge of Disease Progression Hinders the Development of Drugs With Better Efficacy | 53 | 1 |
| Opioids for Neuropathic Pain | 54 | 1 |
| Introduction | 54 | 1 |
| Revenue and Forecasts | 54 | 1 |
| Annual Cost of Therapy | 55 | 1 |
| Treatment Usage Patterns | 56 | 1 |
| Antidepresssants | 56 | 1 |
| Anticonvulsants | 57 | 1 |
| Diseased Population | 58 | 1 |
| Treatment Seeking Population | 59 | 1 |
| Diagnosed Population | 60 | 1 |
| Prescription Population | 61 | 1 |
| Geographical Segmentation | 62 | 2 |
| Drivers and Restraints for the Opioids Market for Neuropathic Pain | 64 | 1 |
| Drivers | 64 | 1 |
| Ageing Population and Increasing Prevalence of Diabetes and HIV | 64 | 1 |
| More Active Treatment Seeking Behavior to Drive Increase in Patient Volumes | 64 | 1 |
| Restraints | 64 | 1 |
| Non-availability of Accurate Tools that Aid Diagnosis is a Hindrance for Market Growth | 64 | 1 |
| Neuropathic pain, which is a chronic pain indication, does not respond well to opioids. | 65 | 1 |
| Opioids Market for Cancer Pain | 65 | 1 |
| Introduction | 65 | 1 |
| The Cancer Pain Drug Market is Fuelled by Opioids | 66 | 1 |
| Revenue and Forecasts | 66 | 1 |
| Annual Cost of Therapy | 67 | 1 |
| Treatment Usage Patterns | 68 | 2 |
| Diseased Population | 70 | 1 |
| Treatment Seeking Population | 71 | 1 |
| Diagnosed Population | 72 | 1 |
| Prescription Population | 73 | 1 |
| Geographical Segmentation | 74 | 2 |
| Drivers and Restraints for the Opioids Market for Cancer Pain | 76 | 1 |
| Drivers | 76 | 1 |
| Rising Incidence of Cancer Drives the Market | 76 | 1 |
| New Modes of Delivery Will Help in Better Management of the Pain for a Longer Duration | 76 | 1 |
| Restraints | 77 | 1 |
| Concerns Over the Risks of Addiction Related to Drug Therapy Affect the Prescription Rate | 77 | 1 |
| Patients Fear That Treatment for Pain will Interfere in Their Cancer Treatment | 77 | 1 |
| Opioids Market for Osteoarthritis Pain | 77 | 1 |
| Introduction | 77 | 1 |
| Revenue and Forecasts | 78 | 1 |
| Annual Cost of Therapy | 79 | 1 |
| Treatment Usage Patterns | 80 | 1 |
| Diseased Population | 81 | 1 |
| Treatment Seeking Population | 82 | 1 |
| Diagnosed Population | 83 | 1 |
| Prescription Population | 84 | 1 |
| Geographical Segmentation | 85 | 2 |
| Drivers and Restraints for the Opioids Market for Osteoarthritis Pain | 87 | 1 |
| Drivers | 87 | 1 |
| Aging population | 87 | 1 |
| Rapid Increase of the Obesity Population | 87 | 1 |
| Lifestyle Changes Increase Incidence of Osteoarthritis | 87 | 1 |
| Restraints | 88 | 1 |
| Opioids Are Associated With Several Side Effects | 88 | 1 |
| Opioids Market for Rheumatoid Arthritis Pain | 88 | 1 |
| Introduction | 88 | 1 |
| Revenue and Forecasts | 88 | 1 |
| Annual Cost of Therapy | 89 | 2 |
| Treatment Usage Patterns | 91 | 1 |
| Diseased Population | 92 | 1 |
| Treatment Seeking Population | 93 | 1 |
| Diagnosed Population | 94 | 1 |
| Prescription Population | 95 | 1 |
| Geographical Segmentation | 96 | 2 |
| Drivers and Restraints for Opioids Market for Rheumatoid Arthritis Pain | 98 | 1 |
| Drivers | 98 | 1 |
| Increasing Incidence and Treatment seeking rate | 98 | 1 |
| Restrains | 98 | 1 |
| Inadequate Awareness of Pain Management | 98 | 1 |
| Adverse Effects | 98 | 1 |
| Opioids Market for Low Back Pain | 99 | 1 |
| Introduction | 99 | 1 |
| Revenue and Forecasts | 99 | 1 |
| Annual Cost of Therapy | 100 | 1 |
| Treatment Usage Patterns | 101 | 1 |
| Diseased Population | 102 | 1 |
| Treatment Seeking Population | 103 | 1 |
| Diagnosed Population | 104 | 1 |
| Prescription Population | 105 | 1 |
| Geographical Segmentation | 106 | 2 |
| Drivers and Restraints for the Opioids Market for Low Back Pain | 108 | 1 |
| Drivers | 108 | 1 |
| Rising Elderly Population Will Drive the Market | 108 | 1 |
| Sedentary Lifestyle increases LBP | 108 | 1 |
| Restraints | 108 | 1 |
| Low Treatment Seeking Rate and Low Prescription Rate Restricts the Market | 108 | 1 |
| Opioids Market for Post-operative Pain | 109 | 1 |
| Introduction | 109 | 1 |
| Revenue and Forecasts | 109 | 1 |
| Annual Cost of Therapy | 110 | 1 |
| Treatment Usage Patterns | 111 | 2 |
| Diseased Population | 113 | 1 |
| Treatment Seeking Population | 114 | 1 |
| Diagnosed Population | 115 | 1 |
| Prescription Population | 116 | 1 |
| Geographical Segmentation | 117 | 2 |
| Drivers and Restraints for the Opioids Market for Post-operative Pain | 119 | 1 |
| Drivers | 119 | 1 |
| Substantial Unmet Need Increases Market Potential | 119 | 1 |
| Titration of Opioids is Convenient in a Surgical Facility | 119 | 1 |
| Restraints | 119 | 1 |
| Expansion of Minimally Invasive Surgical Procedures | 119 | 1 |
| Peri-operative Side Effects | 119 | 1 |
| Opioids Market for Other Indications | 120 | 1 |
| Introduction | 120 | 1 |
| Revenue | 120 | 1 |
| Opioids Market: Geographical Landscape | 121 | 25 |
| The US | 123 | 1 |
| Revenue and Forecasts | 123 | 2 |
| Annual Cost of Therapy | 125 | 1 |
| Treatment Usage Patterns | 126 | 2 |
| Diseased Population | 128 | 1 |
| Treatment Seeking Population | 129 | 1 |
| Diagnosed Population | 130 | 1 |
| Prescription Population | 131 | 1 |
| Top Five Countries in Europe | 132 | 1 |
| Revenue and Forecasts | 132 | 1 |
| Annual Cost of Therapy | 133 | 1 |
| Treatment Usage Patterns | 134 | 1 |
| Diseased Population | 135 | 1 |
| Treatment Seeking Population | 136 | 1 |
| Diagnosed Population | 137 | 1 |
| Prescription Population | 138 | 1 |
| Japan | 139 | 1 |
| Revenue and Forecasts | 139 | 1 |
| Annual Cost of Therapy | 140 | 1 |
| Treatment Usage Patterns | 141 | 1 |
| Diseased Population | 142 | 1 |
| Treatment Seeking Population | 143 | 1 |
| Diagnosed Population | 144 | 1 |
| Prescription Population | 145 | 1 |
| Opioids Market: Pipeline Analysis | 146 | 6 |
| Introduction | 146 | 2 |
| Research and Development Pipeline Neuropathic Pain | 148 | 1 |
| Research and Development Pipeline Cancer Pain | 149 | 1 |
| Profiles of Key Late-Stage Drugs in the Opioids Market | 149 | 1 |
| Fentanyl TAIFUN - AKELA Pharma Inc. | 149 | 1 |
| Mechanism of Action | 149 | 1 |
| Fentanyl Sublingual Spray - INSYS Therapeutics, Inc. | 150 | 1 |
| Oxycodone hydrochloride - Mundipharma International Limited | 150 | 1 |